Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Sep;57(9):801-7.
doi: 10.1007/s00105-006-1180-1.

[Topical Cannabinoid Agonists. An Effective New Possibility for Treating Chronic Pruritus]

[Article in German]
Affiliations
Clinical Trial

[Topical Cannabinoid Agonists. An Effective New Possibility for Treating Chronic Pruritus]

[Article in German]
S Ständer et al. Hautarzt. .

Abstract

Background: Chronic, therapy-resistant pruritus often fails to respond to standard measures so new therapeutic approaches are needed. Recently, the expression of cannabinoid receptors on cutaneous sensory nerve fibers was described, so cannabinoid agonists seem a rational therapeutic option for pruritus.

Patients: In an open application observation 22 patients with prurigo, lichen simplex and pruritus applied an emollient cream containing N-palmitoyl ethanolamine (PEA).

Results: In 14/22 patients a good antipruritic effect could be documented. The average reduction in itch was 86.4%. The therapy was well-tolerated by all patients; neither burning burn nor contact dermatitis was observed.

Conclusions: Topical cannabinoid agonists represent an new effective and well-tolerated therapy for refractory itching of various origins. Creams with a higher concentration may be even more effective with broader indications.

Similar articles

See all similar articles

Cited by 19 articles

See all "Cited by" articles

References

    1. Pain. 2003 Apr;102(3):283-8 - PubMed
    1. Curr Med Chem. 1999 Aug;6(8):721-44 - PubMed
    1. Eur J Pharmacol. 2001 Apr 20;418(1-2):117-25 - PubMed
    1. Curr Med Chem. 2002 Mar;9(6):663-74 - PubMed
    1. Eur J Biochem. 1993 May 15;214(1):173-80 - PubMed

LinkOut - more resources

Feedback